Our results suggest that SCFAs regulate oxidative stress and promote neuronal survival in PD by enhancing EAAT2-mediated glutamate clearance, reducing ROS accumulation, and thereby restoring Nrf2-dependent antioxidant defenses—providing experimental support for SCFA-based therapeutic strategies. This evidence concerns the gene SLC1A2 and Parkinson disease.